One cell, two doors

The somatotroph is the pituitary cell that stores and releases growth hormone. It carries receptors for two distinct signaling systems, and that architecture is what this whole compound family is built around.

The first is the GHRH receptor, which responds to growth-hormone-releasing hormone from the hypothalamus. The second is GHS-R1a - the growth hormone secretagogue receptor type 1a - whose endogenous ligand is acylated ghrelin, the gut peptide better known for appetite signaling.

Two receptors, two separate signaling pathways, converging on the same cell and the same output. A compound acting at one is not redundant with a compound acting at the other, and that is the pharmacological basis for pairing them. We have written separately about whether blended formulations behave differently from stacked individual compounds - this post is about the mechanisms themselves rather than the formulation debate.

Tesamorelin: the GHRH side

Tesamorelin is the full 44-amino-acid sequence of human GHRH with a modification: a trans-3-hexenoyl group, a six-carbon side chain, anchored to the N-terminal tyrosine residue. Its formal designation is [trans-3-hexenoyl]hGHRH(1-44) amide.

That side chain is the entire engineering contribution, and it addresses a specific problem. Native GHRH is cleaved rapidly by dipeptidyl peptidase-IV, giving it a very short circulating life. The hexenoyl modification protects the N-terminus from that cleavage, extending half-life to roughly 26 minutes - against about 12 minutes for sermorelin, the GHRH(1-29) fragment. The compound survives long enough in circulation to reach the pituitary and signal.

Regulatory position, which is unusual for this category. Tesamorelin went through the full FDA drug approval process. It was approved in November 2010 under the brand name Egrifta, developed by Theratechnologies, for a single narrow indication: reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy. It is currently marketed as Egrifta SV and Egrifta WR.

That makes it one of very few compounds in the research-peptide catalog with an actual FDA approval behind it - for one specific indication, in one specific population. The approval is real and it is narrow, and both halves of that sentence matter.

Ipamorelin: the ghrelin-receptor side

Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It emerged from a chemistry program that produced a series of compounds lacking the central Ala-Trp dipeptide of GHRP-1, and it was characterized by its developers as the first selective growth hormone secretagogue.

That word selective is the point of the molecule, and it is worth understanding precisely what it means.

The comparison data. In vitro, ipamorelin released growth hormone from primary rat pituitary cells with potency and efficacy comparable to GHRP-6 - EC₅₀ around 1.3 nmol/L against 2.2 nmol/L for GHRP-6. Pharmacological profiling using GHRP and GHRH antagonists confirmed it acts through a GHRP-like receptor rather than the GHRH receptor.

The selectivity finding. In swine, none of the GH secretagogues tested affected FSH, LH, prolactin or TSH. But GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol. Ipamorelin did not - its ACTH and cortisol levels were not significantly different from those following GHRH stimulation. The original authors described this result as surprising, and it is what separated ipamorelin from the rest of the class. It also does not produce the appetite stimulation characteristic of other ghrelin-receptor agonists.

So the comparison between ipamorelin and other GHRPs is not really about which releases more growth hormone. Potency is broadly similar. It is about how much off-target endocrine activity an experimental design can tolerate - and for research where cortisol or prolactin are confounds, that is a decisive difference.

Mechanistically, binding GHS-R1a - a G-protein coupled receptor - triggers Gq/11-mediated phospholipase C activation, IP₃ generation and intracellular calcium release, culminating in exocytosis of stored GH granules.

One detail that makes GHS-R1a genuinely interesting as a research target: it has among the highest constitutive signaling activity in the entire GPCR family, signaling at roughly 50% of the maximal ghrelin response with no ligand present at all. It also forms heterodimers with a range of other GPCRs including dopamine D1 and D2 receptors and the somatostatin SST5 receptor. This is not a simple on-off switch.

Sorting out the GHRH analog family

Four names circulate in this space and get used loosely. They are different molecules.

• GHRH - the native hypothalamic hormone, 44 amino acids, rapidly degraded.
• Sermorelin - the GHRH(1-29) fragment, the shortest sequence retaining activity. Half-life around 12 minutes.
• Tesamorelin - full-length GHRH(1-44) with the trans-3-hexenoyl stabilization. Half-life around 26 minutes.
• CJC-1295 - a modified GHRH analog available with or without DAC, a drug affinity complex that binds serum albumin and extends half-life dramatically. The with-DAC and without-DAC versions are pharmacologically very different compounds sold under one name, which is a recurring source of confusion.

Ipamorelin belongs to none of this family. It is a GHRP, acting at a different receptor entirely.

Why the pairing exists

Because the two mechanisms are complementary rather than overlapping. GHRH-receptor signaling and GHS-R1a signaling are separate pathways converging on the same cell, and published work has examined their combination on that basis.

There is a second consideration specific to ipamorelin's role. If you are combining a ghrelin-receptor agonist with anything, the off-target profile of the GHRP you choose determines what else moves. A GHRP that raises ACTH and cortisol introduces a second endocrine variable into every result. Ipamorelin's selectivity is why it is the GHRP most often chosen for combination work - not because it releases more GH, but because it releases less of everything else.

Frequently asked questions

Are tesamorelin and ipamorelin the same class of peptide?

No. Tesamorelin is a GHRH analog acting at the GHRH receptor. Ipamorelin is a growth hormone secretagogue acting at GHS-R1a, the ghrelin receptor.

What does GHS-R1a stand for?

Growth hormone secretagogue receptor type 1a. Its endogenous ligand is acylated ghrelin.

Why is ipamorelin called selective?

Because unlike GHRP-6 and GHRP-2, it did not significantly raise ACTH or cortisol in the characterization studies, and it does not produce their appetite stimulation, while releasing comparable growth hormone.

Is tesamorelin FDA-approved?

Yes, for one indication: reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy, approved in 2010 as Egrifta. That approval does not extend to other uses or populations.

What is the difference between tesamorelin and sermorelin?

Sermorelin is the GHRH(1-29) fragment. Tesamorelin is full-length GHRH(1-44) with a trans-3-hexenoyl group protecting it from DPP-IV cleavage, giving it roughly double the half-life.

Why does CJC-1295 come in two versions?

With DAC, it binds serum albumin and circulates far longer; without DAC, it does not. They behave differently and are frequently conflated because both are sold under the same name.

Why are they combined in one vial?

Because the two act at different receptors on the same pituitary cell, so their signals are complementary rather than duplicative.

Where we stand

We supply tesamorelin and a tesamorelin/ipamorelin combination as research materials, and we would rather you understood the receptor pharmacology than bought on the assumption that two peptides are simply better than one. In some experimental designs the combination is the appropriate tool; in others a single mechanism is what the question requires, and adding a second one adds a variable rather than an effect.

Our API is synthesized at a WHO/GMP and ISO 9001 certified laboratory in California and tested to greater than 99% purity, with documentation available on request. For a combination product, ask what the analytical documentation establishes about each component separately - that is a reasonable thing to expect and not every supplier provides it.

Our team is in Chandler, Arizona: (888) 745-1505 or our contact page.

All products sold by BioPure Peptides are intended strictly for in-vitro laboratory and research use only. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.